Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 64, 35-40
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation Therapeutics (SANDERS14A0, GOSS13A0, WEST15A0, HELTSH13A1, FLUME13A1)
- Medical University of South Carolina (UL1TR000062)
- National Institutes of Health (P30 DK089507)
This publication has 31 references indexed in Scilit:
- Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosisJournal of Cystic Fibrosis, 2016
- Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbationsJournal of Cystic Fibrosis, 2015
- Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patientsJournal of Cystic Fibrosis, 2015
- Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosisPediatric Pulmonology, 2012
- Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosisChronic Respiratory Disease, 2012
- Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic FibrosisThe Journal of Pediatrics, 2007
- Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosisThe Journal of Pediatrics, 1999
- Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspectsEuropean Respiratory Journal, 1997